Forbes Austin Allison, founder and general manager of dotloop, argues that it’s not just the availability of streamlined services that guarantees brand success. Companies must also offer a compelling narrative for people to bring these products into their lives. After all, while the creation phase is important, it’s pointless if no one uses it or sees the benefits of the technology. Brands need to create a movement that inspires audience participation.
The Wall Street Journal Career websites like Glassdoor have become regular reading for job seekers. Now chief executives are increasingly perusing their online reviews to find out what employees think of them—to evaluate policies and even to talk back. The public-yet-personal critiques are prompting more company bosses to track and respond to reviews. In the process, they have come to treat them as a necessary evil or a useful management tool, and a performance measure akin to using stock prices to gauge investor confidence.
The Associated Press Keytruda (pembrolizumab) is the first cancer therapy cleared based on a tumor’s genetics instead of the body part it struck first, opening a new treatment option for some patients. The treatment targets a common genetic flaw called a mismatch repair defect that can make solid tumors more susceptible to immunotherapy. Ludwig Johns Hopkins Director Bert Vogelstein said that scientists had previously thought that solid tumors would be the hardest to treat, but the mismatch repair defects act as a beacon to immune cells and represent an Achilles heel for the tumor.
Drug Development & Delivery Lonza announced that following the receipt of all required regulatory approvals, it has completed the acquisition of Capsugel S.A. from KKR for $5.5 billion in cash, including refinancing of existing Capsugel debt of approximately $2 billion. The acquisition of Capsugel, a world leader in advanced oral dosage delivery technologies with a leading position in hard capsules, is expected to be accretive to Lonza’s core earnings per share in the first full year post closing.
Bill Gurley reunites with Zillow’s Spencer Rascoff to talk ‘insane curiosity’ and finding good leaders
GeekWire Bill Gurley, the Benchmark venture capitalist who served for 10 years on the board of directors at Zillow Group, reunited with Spencer Rascoff for the latest episode of the CEO’s podcast “Office Hours.” The two covered a range of topics in the podcast released on Friday, including what Gurley looks for when assessing a person’s leadership potential. Gurley referenced “insane curiosity” and a discussion between Bill Gates and Warren Buffett in which those two billionaires said they shared that trait.
The Milwaukee Journal Sentinel Citi Foundation and Living Cities announced Thursday that they are partnering with Milwaukee and four other cities to fund initiatives that will support local businesses, especially those owned by women and minorities. The partnership is offered through the organizations’ City Accelerator program, which provides municipalities with technical assistance and a relatively small amount of grant funding that they can use to test new programs without risking city tax money. This year, the main focus of the cohort is to solve issues in city procurement processes for local businesses, with an added focus on populations that may be underserved.
Cancer Today Physicians are legally permitted to prescribe drugs approved for one purpose to be used for another, a practice called off-label prescribing. The rise of targeted therapies and immunotherapies is creating new challenges for navigating off-label options. Ludwig Harvard Co-director George Demetri states that even in cancers for which immunotherapy drugs have been approved, not all patients respond to treatment. He recently published a case study on a patient with leiomyosarcoma who was treated with Keytruda and had a very positive response. But other patients with the same disease treated with Keytruda did not benefit.